Aimmune Therapeutics (NASDAQ:AIMT) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Wednesday.

AIMT has been the subject of several other reports. Robert W. Baird assumed coverage on Aimmune Therapeutics in a research note on Wednesday, December 20th. They set an “outperform” rating and a $64.00 target price for the company. Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research note on Saturday, October 21st. Credit Suisse Group increased their target price on Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, ValuEngine cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. Aimmune Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $55.43.

Shares of Aimmune Therapeutics (NASDAQ:AIMT) opened at $39.09 on Wednesday. Aimmune Therapeutics has a 1 year low of $15.97 and a 1 year high of $39.68. The stock has a market cap of $1,990.00 and a P/E ratio of -16.71.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.09. research analysts predict that Aimmune Therapeutics will post -2.51 earnings per share for the current fiscal year.

In related news, insider Douglas T. Sheehy sold 47,425 shares of the firm’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the transaction, the insider now directly owns 34,300 shares in the company, valued at $1,181,292. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stephen George Dilly sold 14,689 shares of the firm’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $26.24, for a total value of $385,439.36. The disclosure for this sale can be found here. Insiders have sold 154,986 shares of company stock worth $4,532,100 over the last 90 days. 17.59% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. lifted its stake in Aimmune Therapeutics by 10.2% during the third quarter. Point72 Asset Management L.P. now owns 1,098,087 shares of the biotechnology company’s stock worth $27,222,000 after purchasing an additional 101,855 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in Aimmune Therapeutics by 4.6% in the third quarter. Schwab Charles Investment Management Inc. now owns 110,580 shares of the biotechnology company’s stock valued at $2,742,000 after buying an additional 4,891 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Aimmune Therapeutics by 3.4% in the third quarter. Wells Fargo & Company MN now owns 61,266 shares of the biotechnology company’s stock valued at $1,519,000 after buying an additional 2,025 shares during the last quarter. Citadel Advisors LLC lifted its stake in Aimmune Therapeutics by 3,092.5% in the third quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after buying an additional 542,111 shares during the last quarter. Finally, Schroder Investment Management Group bought a new stake in Aimmune Therapeutics in the third quarter valued at $961,000. Hedge funds and other institutional investors own 73.34% of the company’s stock.

WARNING: “Aimmune Therapeutics (AIMT) Upgraded to “Buy” by BidaskClub” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://theolympiareport.com/2017/12/27/aimmune-therapeutics-aimt-upgraded-to-buy-by-bidaskclub.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.